CytoDyn (CYDY) Registration Filing summary

Company overview and business model

• Focuses on clinical development and potential commercialization of leronlimab, a product candidate for solid-tumor oncology, including colorectal cancer and metastatic triple-negative breast cancer.

• Pursues additional studies for leronlimab in other oncology indications and is developing a new or modified long-acting version.

• Operates as a Delaware corporation and qualifies as a smaller reporting company, allowing for reduced SEC disclosure requirements.

Financial performance and metrics

• Reports accumulated deficit of approximately $893.3 million as of August 31, 2025.

• Auditors have included explanatory paragraphs regarding substantial doubt as to the company's ability to continue as a going concern for fiscal years ended May 31, 2024 and 2025.

Use of proceeds and capital allocation

• May receive up to $30.0 million in gross proceeds from sales of common stock to YA II PN, Ltd. under a Standby Equity Purchase Agreement.

• Proceeds are expected to be used for working capital, general corporate purposes, and repayment of debt, with management retaining broad discretion over allocation.